uniQure N.V. QURE
At closeNov 12, 2026, 4:01 PM EST
After hours · Nov 12, 4:01 PM ET
- YTD
- +2.93%
- 1 year
- -18.23%
- Market cap
- 1.73B
- Revenue (ttm)
- 20.17M
- EPS (ttm)
- -3.51
- Shares out
- 70.14M
- Forward P/E
- -8.30
- YTD return
- +2.93%
- 1-year return
- -18.23%
- Volume
- 2.13M
- Avg volume
- 2.20M
- Open
- 24.18
- Previous close
- 24.59
- Day's range
- 24.01 – 26.20
- 52-week range
- 8.73 – 51.72
- Beta
- 1.13
- Analysts
- Strong Buy
- Price target
- 59.61 (+142.0%)
- Earnings date
- Mar 1, 2027
5D +2.40 (+10.82%)
Key statistics
- Enterprise value
- 1.62B
- PEG ratio
- 0.00
- Price / sales
- 85.66
- Price / book
- 5.85
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 40.40%
- Free cash flow
- -167.19M
- Total cash
- 668.46M
- Total debt
- 559.64M
- Return on equity
- -88.99%
- Short % of float
- 12.31%
- 50-day average
- 30.35
- 200-day average
- 29.63
Analyst view
Consensus: strong buy
- Target (low)
- 27.59
- Target (mean)
- 59.61
- Target (high)
- 93.61
- Strong buy1
- Buy10
- Hold2
- Sell0
- Strong sell0
Next earnings
Mar 1, 2027
Expected Mar 1, 2027. Consensus EPS estimate -0.73138.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 1, 2027 | Dec 30, 2026 | -0.88 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | -0.91539 | -0.88 | +0.04 | +3.87% |
| Jul 29, 2026 | Jun 30, 2026 | -0.82228 | -1.22 | -0.40 | -48.37% |
| May 5, 2026 | Mar 31, 2026 | -0.88 | -0.85 | +0.03 | +3.41% |
| Mar 2, 2026 | Dec 31, 2025 | -0.93 | -0.56 | +0.37 | +39.78% |
| Nov 10, 2025 | Sep 30, 2025 | -0.85 | -1.38 | -0.53 | -62.35% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 5, 2026 | Barclays | down | Overweight | Equal-Weight |
| Oct 2, 2026 | RBC Capital | main | Outperform | Outperform |
| Sep 30, 2026 | Goldman Sachs | main | Neutral | Neutral |
| Jul 30, 2026 | Wells Fargo | main | Overweight | Overweight |
| Jul 30, 2026 | Wolfe Research | up | Peer Perform | Outperform |
| Jul 30, 2026 | Barclays | main | Overweight | Overweight |
About uniQure N.V.
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Netherlands
- Website
- uniqure.com
News
uniQure Q3 2026 Earnings Call Transcript 
uniQure Q3 EPS $(0.88) Beats $(0.92) Estimate, Sales $5.200M Miss $6.178M Estimate 
FDA Pushes uniQure Huntington Therapy Forward, Analyst Brushes Off Softening Signals 
Barclays Downgrades uniQure to Equal-Weight, Lowers Price Target to $28 
RBC Capital Maintains Outperform on uniQure, Lowers Price Target to $48 - Goldman Sachs Maintains Neutral on uniQure, Lowers Price Target to $31
Hewlett Packard Enterprise, Capital Bancorp, FormFactor And Other Big Stocks Moving Higher On Wednesday 
12 Health Care Stocks Moving In Tuesday's Intraday Session 
Crude Oil Down 1%; US Job Openings Fall In August 
Why Is uniQure Stock Sinking on Tuesday?
Your note
Sign in to keep a note on QURE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ABI-SAAB WALID | Officer | Sale | Jun 29, 2026 | 148,235 |
| BALACHANDRAN MADHAVEN | Director | Sale | Jun 16, 2026 | 43,254 |
| GUT ROBERT | Director | Sale | Jun 10, 2026 | 32,259 |
| JACQUES RACHELLE SUZANNE | Director | Sale | Jun 10, 2026 | 33,903 |
| KAPUSTA MATTHEW C | Chief Executive Officer | Sale | Jul 1, 2026 | 519,227 |
| KLEMT CHRISTIAN | Chief Financial Officer | Stock Award(Grant) | Mar 3, 2026 | 226,581 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Avoro Capital Advisors LLC | 9.59% | 6,727,777 | 165.71M | Jun 29, 2026 |
| JPMORGAN CHASE & CO | 6.94% | 4,867,755 | 119.89M | Jun 29, 2026 |
| RTW Investments LP | 5.62% | 3,941,572 | 97.08M | Jun 29, 2026 |
| State Street Corporation | 4.14% | 2,903,825 | 71.52M | Jun 29, 2026 |
| Aberdeen Group plc | 2.73% | 1,915,227 | 47.17M | Sep 29, 2026 |
| Blackrock Inc. | 2.68% | 1,877,453 | 46.24M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.90% | 2,031,760 | 50.04M | Sep 29, 2026 |
| abrdn Healthcare Investors | 1.77% | 1,240,256 | 30.55M | Jun 29, 2026 |
| J.P. Morgan Mutual Fd. Investment TRT-JPMorgan Growth Advantage Fd. | 1.76% | 1,237,920 | 30.49M | Jun 29, 2026 |
| JPMorgan Trust II-JPMorgan Mid Cap Growth Fund | 1.37% | 959,052 | 23.62M | Jun 29, 2026 |
| abrdn World Healthcare Fund | 1.13% | 792,575 | 19.52M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.08% | 758,041 | 18.67M | Jun 29, 2026 |